Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Black Diamond Therapeutics, Inc. (BDTX) had Return on Tangible Equity of -8.66% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-9.04M |
|
-- |
|
-- |
|
$11.26M |
|
$-11.26M |
|
$2.22M |
|
$-9.04M |
|
$-9.04M |
|
$-9.04M |
|
$-9.04M |
|
$-9.04M |
|
$-9.04M |
|
$-11.26M |
|
$-11.23M |
|
57.23M |
|
57.23M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$122.97M |
|
$0.34M |
|
$9.96M |
|
$132.92M |
|
$14.53M |
|
-- |
|
$14.09M |
|
$28.62M |
|
$104.30M |
|
$104.30M |
|
$104.30M |
|
57.30M |
|
| Cash Flow Statement Financials | |
$-10.23M |
|
$19.50M |
|
$-0.18M |
|
$21.82M |
|
$30.90M |
|
$9.08M |
|
$1.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.66% |
|
|
Return on Tangible Equity |
-8.66% |
-6.80% |
|
-8.66% |
|
$1.82 |
|
$-0.18 |
|
$-0.18 |
|